Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970858 | 0.94 | NAMPT (0.52) | NAMPTLSSACACBRUNX1STAT3 | |
| SCHEMBL19970865 | 0.92 | STAT3 (0.51) | ACACBRUNX1STAT3CHEK2BCHE | |
| SCHEMBL19970885 | 0.91 | BCHE (0.56) | LSSACACBRUNX1CHEK2BCHE | |
| SCHEMBL19970737 | 0.90 | SLC2A1 (0.57) | ACACBSTAT3BCHEACHEHDAC6 | |
| SCHEMBL19970730 | 0.88 | RUNX1 (0.54) | NAMPTRUNX1SLC2A1CYP11B1CYP11B2 | |
| SCHEMBL19970864 | 0.86 | STAT3 (0.51) | NAMPTACACBSTAT3MEN1KMT2A | |
| SCHEMBL19970849 | 0.85 | RUNX1 (0.58) | LSSACACBRUNX1STAT3CHEK2 | |
| SCHEMBL19970884 | 0.84 | LSS (0.54) | LSSRUNX1STAT3CHEK2BCHE | |
| SCHEMBL19970729 | 0.83 | NAMPT (0.49) | NAMPTRUNX1CYP11B1CYP11B2 | |
| SCHEMBL19970736 | 0.83 | SIGMAR1 (0.52) | ACACBSTAT3MEN1KMT2ASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | NAMPT 1651/4885LSS 937/4885ACACB 4387/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | NAMPT 1651/4885LSS 937/4885ACACB 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.